Sustiva, Efavirenz Newswire (Page 2)

Sustiva, Efavirenz Newswire (Page 2)

Comprehensive Real-Time News Feed for Sustiva, Efavirenz (generic). (Page 2)

Results 21 - 40 of 135 in Sustiva, Efavirenz (generic)

  1. Tenofovir resistance may develop in more than half of patients...Read the original story w/Photo

    Feb 3, 2016 | Aidsmap

    Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.

    Comment?

  2. Tenofovir Resistance Is Common in Those Failing HIV MedsRead the original story w/Photo

    Feb 2, 2016 | POZ

    Among people who fail HIV treatment regimens, resistance to tenofovir is common, ranging between 20 and 57 percent among populations studied, and the incidence of such acquired resistance is likely increasing. Publishing their findings in The Lancet, researchers examined data on 1,926 HIV-positive people from 36 countries who experienced treatment failure between 1998 and 2015.

    Comment?

  3. Case report: Severe central nervous system manifestations associated...Read the original story

    Feb 1, 2016 | BioMed Central

    Efavirenz, widely used as part of antiretroviral drug regimens in the treatment of paediatric human immunodeficiency virus infection, has central nervous system side effects. We describe four children presenting with serious, persistent central nervous system adverse events who were found to have elevated plasma efavirenz concentrations as a result of carrying CYP2B6 single nucleotide polymorphisms, known to play a role in the metabolism of EFV.

    Comment?

  4. Tenofovir resistance may develop after HIV treatment failure in over half in sub-Saharan AfricaRead the original story w/Photo

    Feb 1, 2016 | Aidsmap

    Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.

    Comment?

  5. Resistance to one of the most effective anti-HIV drugs on the market is alarmingly widespreadRead the original story w/Photo

    Jan 29, 2016 | Silicon Alley Insider

    It's one of the most common and most effective anti-HIV drugs on the market, but resistance to tenofovir is alarmingly widespread, according to a new study . With the prevalence of resistance significantly higher than anticipated, the findings are particularly worrying given that scientists believed this to be a drug that HIV would be less prone to evolving defense mechanisms against.

    Comment?

  6. Elbasvir-Grazoprevir Approved for Chronic Hepatitis C InfectionRead the original story

    Jan 29, 2016 | ASHP

    FDA on January 28 approved the marketing of elbasvir-grazoprevir oral tablets for the treatment of chronic hepatitis C virus genotype 1 and 4 infection in adults. According to the labeling for the combination product, each tablet contains 50 mg of the HCV NS5A inhibitor elbasvir and 100 mg of grazoprevir, an HCV NS3/4A protease inhibitor.

    Comment?

  7. HIV resistance to favored treatment not uncommonRead the original story w/Photo

    Jan 29, 2016 | Fox News

    HIV, or human immunodeficiency virus, particles in purple, cause the disease AIDS. Credit: CDC/ Dr. A. Harrison; Dr. P. Feorino Resistance to a key HIV drug is common worldwide and could mean trouble for treating and preventing the virus that causes AIDS, according to a new study.

    Comment?

  8. CYP2B6*6 genotype and high efavirenz plasma concentration but not...Read the original story

    Jan 28, 2016 | The Pharmacogenomics Journal

    E-mail: [email protected] We investigated the influence of efavirenz - or nevirapine -based antiretroviral therapy on lumefantrine plasma exposure in HIV-malaria-coinfected patients and implication of pharmacogenetic variations. A total of 269 HIV patients with uncomplicated falciparum malaria on NVP-based ART , EFV-based ART or not receiving ART were enrolled and treated with artemether-lumefantrine.

    Comment?

  9. Efavirenz-based treatment is safe and effective for young children...Read the original story w/Photo

    Jan 19, 2016 | Aidsmap

    Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.

    Comment?

  10. Not having enough food linked with lower chances of sustained viral...Read the original story w/Photo

    Jan 12, 2016 | Aidsmap

    Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.

    Comment?

  11. PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023Read the original story

    Dec 30, 2015 | Sys-Con Media

    As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline's Retrovir , was approved in 1987, major improvements have been made in the field of antiretroviral therapy .

    Comment?

  12. Read the Interactions between HIV treatment and recreational drugs factsheetRead the original story w/Photo

    Dec 28, 2015 | Aidsmap

    This is the case both for prescribed medicines and recreational drugs, although there is much less medical research on drug interactions with illicit drugs. But we do know that some anti-HIV drugs and some recreational drugs are metabolised by the same pathways in the body.

    Comment?

  13. Pharmacokinetic drug interactions with clopidogrel: updated review...Read the original story

    Dec 15, 2015 | CiteULike

    Coprescribing of clopidogrel and other drugs is common. Available reviews have addressed the drug-drug interactions when clopidogrel is as an object drug, or focused on combination use of clopidogrel and a special class of drugs.

    Comment?

  14. Research and Markets: PharmaPoint: Human Immunodeficiency Virus (HIV) ...Read the original story

    Dec 14, 2015 | Information Technology

    Research and Markets: PharmaPoint: Human Immunodeficiency Virus - Global Drug Forecast and Market Analysis to 2023 for the $15 Billion Industry The value of the Human Immunodeficiency Virus treatment market will increase marginally from just over $14 billion in 2013 to approach $15.3 billion by 2023, representing a low Compound Annual Growth Rate of 0.9% across the nine major markets of the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, and China. While the overall market size will not undergo major changes, the treatment landscape is expected to experience a paradigm shift towards integrase inhibitor drugs and single-tablet regimens .

    Comment?

  15. PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023Read the original story w/Photo

    Dec 11, 2015 | SBWire

    Human immunodeficiency virus is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections.

    Comment?

  16. Tobira Therapeutics Inc. Announces Data Presentations Highlighting Cenicriviroc AtRead the original story

    Dec 8, 2015 | BioSpace

    Tobira and its key collaborators presented two abstracts and a sponsor presentation on cenicriviroc , the company's lead CCR2/5 antagonist; CENTAUR, the company's Phase 2b study evaluating CVC in NASH; and enhanced liver fibrosis index data from the company's completed HIV Phase 2b study. "The clinical data presented at HEP DART continues to expand our understanding of how CVC may play an important role for the treatment of NASH with liver fibrosis," said , M.D., chief medical officer at Tobira.

    Comment?

  17. WHO issues recommendations on linkage to care, retention, to help bring HIV treatment to allRead the original story w/Photo

    Dec 1, 2015 | Aidsmap

    Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.

    Comment?

  18. On World AIDS Day, Mylan Announces Plans To Be The First To Market...Read the original story

    Nov 30, 2015 | BioSpace

    On World AIDS Day, Mylan Announces Plans To Be The First To Market Newly-Recommended Antiretroviral Treatment For $99 Per Patient, Per Year /PRNewswire/ -- Mylan N.V. today announced that it expects to be the first to launch, upon regulatory approval and for developing country markets funded by international donors, TLE400 for per patient, per year. Mylan partnered with the Clinton Health Access Initiative to develop TLE400.

    Comment?

  19. WHO issues recommendations on linkage to care, retention, to help bring HIV treatment to allRead the original story w/Photo

    Dec 1, 2015 | Aidsmap

    Our award-winning series of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. A range of interactive tools to support people living with HIV to get involved in decisions about their treatment and care.

    Comment?

  20. Three new agreements announced with potential to expand access to...Read the original story w/Photo

    Dec 1, 2015 | PRWeb

    UNITAID, The Clinton Health Access Initiative, Inc. and UNAIDS announced three new agreements that could increase access to more sustainable HIV drug treatments at reduced prices. Bringing effective new HIV drugs to the millions of people who have still not initiated treatment is a big challenge in global health today.

    Comment?